A structure consisting of substituted hydantoin linked to a 5-(halophenyl) furan-2-yl group via an amide bond was identified as a promising scaffold for development of low-molecular- weight therapeutic agents to treat vascular dysfunction, including ischemia/reperfusion injury. Among the compounds synthesized, 5-(3, 5-dichlorophenyl)-N-{2, 4-dioxo-3-[(pyridin- 3-yl) methyl] imidazolidin-1-yl}-2-furamide (17) possessed the most potent inhibitory ...